Promoted Content Promoted Content


Find Neurology Drugs in Phase II Clinical Development in CANADA


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2021


            Company provided an update on its research and development initiatives including the FDA Phase 2 study with ketamine to treat Parkinson’s disease, treatment-resistant depression, and the development of novel microneedle patches for delivering psychedelics of it.